Editorial Expression of Concern: p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells

Oncogene. 2024 Sep;43(40):3018. doi: 10.1038/s41388-024-03147-5.
No abstract available

Publication types

  • Editorial
  • Expression of Concern

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Boronic Acids / pharmacology
  • Bortezomib* / pharmacology
  • Cell Line, Tumor
  • Humans
  • Multiple Myeloma* / drug therapy
  • Multiple Myeloma* / genetics
  • Multiple Myeloma* / pathology
  • Pyrazines / pharmacology
  • p38 Mitogen-Activated Protein Kinases* / metabolism

Substances

  • Bortezomib
  • p38 Mitogen-Activated Protein Kinases
  • Antineoplastic Agents
  • Pyrazines
  • Boronic Acids